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Beneficial effects of saffron (Crocus sativus L.) in 
ocular pathologies, particularly neurodegenerative 
retinal diseases
Introduction
Neurodegenerative diseases such as glaucoma and age-related 
macular degeneration (AMD), among others (e.g., retinitis 
pigmentosa and diabetic retinopathy), are the main causes of 
irreversible blindness in the world. In these pathologies, the 
mechanisms that induce neuronal death are still unknown, 
but at present it is believed that they share some pathogenic 
mechanisms. The impairment in mitochondrial function 
(Lee et al., 2011; Lascaratos et al., 2012; Chrysostomou et al., 
2013), the dysfunction in the ubiquitin–proteasome system 
(Campello et al., 2013), the buildup of misfolded proteins 
and glutamate excitotoxicity (Gazulla and Cavero-Nagore, 
2006; Guimarães et al., 2009), the oxidative stress (Uttara et 
al., 2009), and the activation of glial cells and inflammatory 
processes (Verkhratsky et al., 2014; Brown and Vilalta, 2015) 
could be some of these pathogenic mechanisms, which could 
act individually or jointly (Ghiso et al., 2013). All these neu-
rodegenerative ocular diseases have treatments that have a 
positive impact on the preservation of vision and slow the 
progression of these pathologies. However, there is still no 
cure. Currently, natural products derived from plants are 
being used to develop new therapies, due to their potential 
pharmacological effects and low toxicity profiles (Moshiri et 
al., 2014). In addition, the effectiveness of natural products 
to slow neurodegenerative processes through different path-
ways is being studied. Among these products is saffron (dried 
stigmas of Crocus sativus L.), a spice which is well known 
and used for culinary purposes. The main goal of the present 
review is to analyze the different studies in which saffron 
extract has been used for treatment of various neurodegener-
ative ocular diseases and other ocular pathologies. 
Search Strategy and Selection Criteria
The search strategy was based on a focussed literature review. 
Databases used to identify the most relevant papers included 
PubMed and Google Scholar. Search keywords used in dif-
ferent forms included: “saffron”, “crocin”, “crocetin”, “safranal”, 
“neurodegeneration”, retinal diseases”, “ocular diseases”. Ar-
ticles published in the last ten years or relevant publications 
were selected for this review article. 
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Saffron Extracts and Its Constituents
Crocus sativus L. (C. sativus) is a ﬂowering plant belonging 
to the Iridaceae family  (Khazdair et al., 2015). This spice has 
been used in food preparation since ancient times (Basker 
and Negbi, 1983) and is mainly cultivated in the European 
Mediterranean region and Asia, with Iran as the main pro-
ducer country (85%) (Milajerdi and Mahmoudi, 2014; Ghaf-
fari and Roshanravan, 2019). Saffron has been part of many 
pharmacological formulas used from the 16th century to 
today, being included in the Catalogues of Medicinal Plants 
and in European Pharmacopoeias (José Bagur et al., 2017). 
In the stigmas of C. sativus it is possible to find more than 
100 metabolites, including isomers of carotenoids (α-croce-
tin, glycoside crocin (yellow color), picocrocin, and the agly-
cone-safranal (saffron aroma)) and antioxidants (zeaxanthin, 
vitamin B12 and lycopene) (Assimopoulou et al., 2005; 
Karimi et al., 2010; Serrano-Díaz et al., 2012; Khazdair et al., 
2015), which have been demonstrated to have several phar-
macological and therapeutic uses (Srivastava et al., 2010). 
The therapeutic activity of saffron may be due to the crocetin 
and crocin, its main bioactive components (Bathaie et al., 
2014; Rameshrad et al., 2018; Hashemi and Hosseinzadeh, 
2019). It has been observed, in both humans and animals, 
that crocin is hydrolyzed to crocetin during the process of 
intestinal absorption (Xi et al., 2007). Once in circulation, 
crocetin, due to its poor binding to albumin, reaches differ-
ent tissues and can cross the blood-brain barrier (BBB) (Asai 
et al., 2005; Hosseini et al., 2018a). Crocetin can traverse the 
BBB by passive transcellular diffusion, as demonstrated in 
an in vitro study (Lautenschläger et al., 2015). In addition, 
a mouse in vivo study showed that trans-crocin 4, the most 
abundant type of crocin in saffron, can penetrate the BBB 
and accumulate in the brain (Karkoula et al., 2018).
It has been demonstrated that crocetin is responsible for 
the main therapeutic properties of saffron (Hashemi and 
Hosseinzadeh, 2019). Christodoulou et al. (2019) showed 
that after oral saffron extract administration, crocetin levels 
in the blood were higher than those following intravenous 
administration, due to the quick intestinal absorption of 
trans-crocetin. In addition, Zhang et al. (2017b) observed 
that oral administration of equal molar concentrations 
of crocin and crocetin showed that crocin reaches higher 
concentrations of crocetin in rat serum than oral crocetin 
administration, suggesting that oral administration of crocin 
has an advantage over oral crocetin administration.
Saffron’s General Therapeutic Properties
In addition to its organoleptic attributes, saffron and its 
main bioactive derivatives have been used routinely in tra-
ditional medicine because of their numerous therapeutic 
properties, such as protection against ischemia, as well as 
their anticonvulsant, antidepressant, anxiolytic, hypolip-
idemic, anti-atherogenic, anti-hypertensive, antidiabetic, 
and anti-cancer properties (Ríos et al., 1996; Kianbakht and 
Hajiaghaee, 2011; Christodoulou et al., 2015; Hosseini et 
al., 2018b; Ghaffari and Roshanravan, 2019). Among their 
pharmacological effects, a potent stimulatory effect has been 
reported for C. sativus extract and safranal on β2-receptors, 
the blocking effect of safranal on muscarinic receptors, and 
the inhibition of histamine (H1) receptors by C. sativus 
(Boskabady et al., 2010). Recently, different mechanisms of 
action have been attributed to crocetin, among which are 
the increase of oxygen transport during shock, the decrease 
of pro-inflammatory molecules, protection against oxidative 
stress, and induction of apoptosis in cancer cells (Hashemi 
and Hosseinzadeh, 2019). 
The therapeutic properties of saffron may be due to the 
important anti-inflammatory, antioxidant, and anti-apop-
totic properties of its bioactive components (Hosseinzadeh 
and Younesi, 2002; Yamauchi et al., 2011; Ohno et al., 2012; 
Poma et al., 2012).
There is currently a growing interest in the effects of the 
bioactive components of saffron on human health due to 
their antioxidant properties (Moallem et al., 2014). Safranal 
and crocin show antioxidant activities through scavenging 
free radicals (Assimopoulou et al., 2005; Farahmand et al., 
2013; Mashmoul et al., 2013). The mode of action of these 
carotenoids could (Bukhari et al., 2018; Korani et al., 2019): i) 
modulate the detoxifying enzymes involved in counteracting 
oxidative stress, ii) decrease telomerase activity, iii) increase 
the pro-apoptotic effect in cancerous cells, iv) change the 
expression of genes related to the redox system of cells and 
inhibit the synthesis of DNA, RNA, and proteins, v) alter the 
stress marker genes in the endoplasmic reticulum system, vi) 
make changes in epigenetics, and vii) through the ability to 
form a strong union of crocetin with tRNA.
It has also been seen that saffron has anti-inflammatory ef-
fects. These effects could be due to its free-radical scavenging 
activity. Inflammatory conditions are triggered by the release 
of reactive oxygen species and the release of several cytokines 
from microglia, macrophages, and monocytes, among others 
(Poma et al., 2012). The anti-inflammatory effects of saffron 
could be due to (Soeda et al., 2001; Falsini et al., 2010; Nam 
et al., 2010; Natoli et al., 2010; Wang et al., 2015; Korani et 
al., 2019; Zeinali et al., 2019) i) the regulation of genes that 
control the release of pro-inflammatory cytokines from glial 
cells, such as interleukin (IL)-6, IL-1β, and IL-2; ii) blocking 
the tumor necrosis factor (TNF)-α released by microglial 
cells that induces DNA fragmentation, thereby suppressing 
cell death; iii) modulation of the expression of genes encod-
ing adhesion molecules (vascular cell adhesion protein 1, 
intercellular adhesion molecule 1, and E-selectin); iv) the 
reduction of the mRNA expression of some pro-inflamma-
tory enzymes (inducible nitric oxide synthase and cyclooxy-
genase-2); and v) modulation of the inflammatory pathways 
(nuclear factor-κB and mitogen-activated proteins kinase).
Crocin administration prevents BBB disruption, inhibit-
ing, in part, the alterations of tight junctions due to ischemia 
in a middle cerebral artery occlusion model. BBB integrity 
is important to protect the neuronal environment from 
harmful elements, such as infiltrated inflammatory cells and 
cytokines, which can induce neuronal damage (Zhang et al., 
2017a).
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In addition, saffron shows an anti-apoptotic effect. In 
neuronal damage, an inhibitory effect on Bcl-2, Bax, and 
caspase-3 expression has been observed after crocin supple-
mentation (Yamauchi et al., 2011). 
Finally, saffron has been related to the cannabinoid sys-
tem. In an experimental model of retinal damage associated 
with continuous exposure to bright light, it was observed 
that the administration of saffron counteracted the harmful 
effects on the retina mediated by the cannabinoid system, 
thereby suggesting that saffron and cannabinoid receptors 
could share the same mechanism of action in neuroprotec-
tion (Maccarone et al., 2016).
Toxicity and Adverse Side Effects of Saffron
Some studies have focused on assessing the toxicity of saf-
fron mainly due to dose-dependent adverse effects. These 
toxic effects of saffron have been documented for daily doses 
of more than 5 g, becoming lethal for doses of 20 g (Schmidt 
et al., 2007). Low doses of saffron between potentially toxic 
ranges can cause dizziness, nausea, vomiting and diarrhea, 
but high doses can exacerbate these toxic effects causing 
numbness, tingling of the extremities, cutaneous and con-
junctival yellow pigmentation and spontaneous bleeding 
on the lips, eyelids, nose, and uterus (Schmidt et al., 2007; 
WHO, 2007; Modaghegh et al., 2008). Oral administration 
of more than 5 g can cause thrombocytopenia, localized skin 
hemorrhages, stimulating effects of the uterus, emmena-
gogue and abortive effects, so it should be used with caution 
in patients with bleeding disorders, anticoagulant treatment 
and pregnancy (Hepner et al., 2002; WHO, 2007; Moshiri et 
al., 2014; Heitmar et al., 2019). Therefore, the main clinical 
and experimental studies performed use milligram doses, 
which have been shown to have no adverse side effects. 
Clinical studies with saffron tables in doses of 200 and 400 
mg showed no clinically important alterations. The patients 
treated in this study exhibited changes of normal range in 
some hematological and biochemical parameters (Moda-
ghegh et al., 2008).
Saffron and Neurodegeneration
Recently, the neuroprotective role of dietary saffron has 
generated great interest. Extracts of C. sativus and its com-
ponents can exert neuroprotection in neurodegenerative 
diseases, such as Alzheimer’s and Parkinson’s diseases, be-
cause they can interact with the glutamatergic, cholinergic 
and dopaminergic systems (Khazdair et al., 2015). Neuro-
protective effects have been observed in both experimental 
models (Ahmad et al., 2005; Geromichalos et al., 2012; Pu-
rushothuman et al., 2013; Khazdair et al., 2015) and clinical 
studies in patients (Akhondzadeh et al., 2010; Khazdair et 
al., 2015). Clinical studies have demonstrated that saffron 
oral administration in mild-to-moderate Alzheimer’s disease 
patients ameliorated cognitive function (Akhondzadeh et 
al., 2010). Safranal prevented neuronal loss due to amyloid β 
(Aβ) in CA1’s hippocampal area, via decrease of apoptosis, 
oxidative stress, inflammation, cholinesterase activity, and 
neutrophil infiltration, and also through the preservation of 
mitochondrial integrity in an Alzheimer’s disease rat model 
(Baluchnejadmojarad et al., 2019). Trans-crocin-4 inhibited 
Aβ fibrillogenesis in vitro (Papandreou et al., 2006). In a spo-
radic Alzheimer’s disease model in rats (induced by intrace-
rebroventricular injection of streptozotocin), treatment with 
saffron extract improved cognitive impairment (Khalili and 
Hamzeh, 2010; Khalili et al., 2010). 
In a Parkinson’s disease model, it was shown that exercise 
and crocin supplementation, due to their anti-inflammato-
ry and antioxidant properties, could ameliorate motor and 
memory deficits (Shahidani et al., 2019). In addition, C. sa-
tivus hydroethanolic extract has a neuroprotective effect on 
the nervous system of the meriones shawi rodent, suggesting 
that saffron could be a possible therapeutic agent in neuro-
degenerative disorders, including dopaminergic and norad-
renergic injuries trigged by heavy metals like in Parkinson’s 
disease (Tamegart et al., 2019). Crocetin administration in 
an induced animal model of Parkinson’s disease 6-hydroxy-
dopamine reduced dopamine utilization, thereby exerting a 
neuroprotective effect (Ahmad et al., 2005). In the 1-meth-
yl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson-
ism in mice, saffron pre-treatment reduced dopaminergic 
cell loss in the nigra pars compacta and retina (Purushothu-
man et al., 2013). 
Saffron and Ocular Neurodegenerative 
Diseases
It has been postulated that saffron supplementation can ex-
ert beneficial effects in ocular neurodegenerative diseases, 
such as glaucoma, AMD, diabetic retinopathy, and retinitis 
pigmentosa, among others (Bonyadi et al., 2014; Sepahi et 
al., 2018; Broadhead et al., 2019) (Table 1 and Figure 1).
Glaucoma
Glaucoma is a neurodegenerative disease related to retinal 
ganglion cell (RGC) loss and microglial activation. At pres-
ent, treatment mainly aims to control intraocular pressure 
but, on occasion, this does not prevent the disease’s progres-
sion. Thus, today, neuroprotection could constitute one of 
the main objectives of recent studies.
The over-stimulation of a type of ionotropic glutamate 
receptor, such as N-methyl-D-aspartate, is related to several 
retinal pathologies, including glaucoma. In a retinal damage 
experimental mouse model induced by intravitreal N-meth-
yl-D-aspartate injection, oral crocetin administration re-
duced retinal impairment partly by inhibiting caspases and 
therefore decreasing apoptosis of retinal ganglion cells (Ohno 
et al., 2012).
Microglial activation is directly related to neurodegener-
ation in glaucoma (Gallego et al., 2012; De Hoz et al., 2013; 
Rojas et al., 2014; de Hoz et al., 2018). Stimulation with li-
popolysaccharide, which is used as an inflammatory model 
that triggers microglial activation, causes the release of fac-
tors such as TNF-α, cyclooxygenase-2, inducible nitric oxide 
synthase and IL-1β, among others, which are mediators 
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of the inflammatory process (Nam et al., 2010). Moreover, 
membrane-bound fractalkine (CX3CR1) deficiency increas-
es microglial neurotoxicity and RGC loss (Wang et al., 2014). 
Pretreatment of BV2 microglia cells cultured with crocin 
reversed the morphological changes, including down-regu-
lation of CX3CR1 expression, and up-regulation of TNF-α, 
cyclooxygenase-2, inducible nitric oxide synthase, and IL-1β 
in a lipopolysaccharide in vitro model (Lv et al., 2016).
In many ocular diseases, such as glaucoma, retinal isch-
aemia plays an important role by inducing neuronal cell 
death (Ishizuka et al., 2013). Crocin and crocetin inhibit 
RGC death in mouse and rat models of ischemia/reperfusion 
(Ishizuka et al., 2013; Qi et al., 2013; Chen et al., 2015). The 
possible neuroprotective effects against ischemic damage 
could be due to oxidative stress inhibition through different 
mechanisms. These mechanisms include a decrease in the 
number of positive TUNEL cells and 8-hydroxy-2-deox-
yguanosine positive cells (a good biomarker of oxidative 
damage), and the phosphorylation levels of c-Jun, JNK, p38, 
and NF-κB, which are elevated after retinal damage (Ishizuka 
et al., 2013).
Recently, in a mouse model of glaucoma, the anti-inflam-
matory and neuroprotective effect of the saffron extract 
(standardized to 3% crocin content) (Almodóvar et al., 
2018), has been demonstrated (Fernández-Albarral et al., 
2019). In this model, an increase of ocular hypertension 
(OHT) was induced by unilateral laser photocoagulation 
of the limbal and episcleral veins. Treatment with saffron 
extract reduced microglial cell number and the signs of mi-
croglial activation, including process retraction and soma 
size, both in OHT eye and the normotensive contralateral 
eye. Furthermore, down-regulation of P2RY12 induced by 
the OHT increase was reversed in part by saffron extract 
supplementation (Fernández-Albarral et al., 2019). Up-reg-
ulation of P2RY12 occurs immediately after damage, and a 
few hours later the P2RY12 expression is down-regulated, 
finally becoming undetectable in highly activated microg-
lial cells (Haynes et al., 2006). Thus, this result indicates 
that saffron extract could be exerting an anti-inflammatory 
effect through the regulation of P2RY12 expression (Fernán-
dez-Albarral et al., 2019). Finally, in this model, saffron’s 
neuroprotective role has also been demonstrated; saffron 
Table 1 Studies of the beneficial effects of saffron, crocin, crocetin, or safranal supplementation in ocular diseases
Disease dose Experimental model/cell culture/clinical studies Studies
Glaucoma Crocetin: 20 or 100 mg/kg NMDA-induced retinal damage; mouse Ohno et al., 2012
Crocin and crocetin LPS inflammatory model; microglial cell culture Nam et al., 2010
Crocin LPS inflammatory model; microglial cell culture Lv et al., 2016
Crocetin: 20 mg/kg Retinal ischemia model; mouse Ishizuka et al., 2013
Crocin: 50 mg/kg Retinal ischemia/reperfusion model; rat Chen et al., 2015
Crocin: 5, 25, or 50 mg/kg Retinal ischemia/reperfusion model; rat Qi et al., 2013
Saffron extract: 60 mg/kg OHT laser-induced model; mouse Fernández-Albarral et al., 2019
Saffron: 1 g POAG clinical study Hecht et al., 2019
Saffron extract: 30 mg POAG clinical study Bonyadi et al., 2014
AMD Saffron: 1 mg/kg Light exposure-induced damage; rat Bisti et al., 2014
Crocetin: 10–100 mg/kg Light exposure-induced damage; rodent Yamauchi et al., 2011
Saffron: 1 mg/kg Light exposure-induced damage; rat Di Marco et al., 2019
Crocin and crocetin Ischemia model; rat Xuan et al., 1999
Saffron: 25 μg/kg ATP-induced damage Corso et al., 2016
Saffron: 20 mg Early AMD clinical study Falsini et al., 2010
Saffron: 20 mg Early AMD clinical study Piccardi et al., 2012
Saffron: 20 mg Early AMD clinical study Marangoni et al., 2013
Saffron: 30 mg Wet and dry AMD clinical study Lashay et al., 2016
Diabetic retinopathy Crocin Microglial cell culture Yang et al., 2017
Crocin: 5–15 mg Diabetic maculopathy Sepahi et al., 2018
Retinitis pigmentosa Safranal: 400 mg/kg RP model; rat Fernández-Sánchez et al., 2012
Saffron: 1 mg/kg Light exposure-induced damage; rat Marco et al., 2013
Saffron: 1 mg/kg Light exposure-induced damage; rat Maccarone et al., 2008
Crocetin: 10–100 mg/kg; 3 μM Light exposure-induced damage; mouse/tunicamycin 
and hydrogen peroxide-induced damage; cell culture
Yamauchi et al., 2011
Myopia Crocetin: 10–100 mg/kg Lens-induced myopia model; murine Mori et al., 2019a
Crocetin: 7.5 mg Clinical study; children Mori et al., 2019b
Retino-blastoma Crocin: 0, 5, 10, 20, 40, 80 μM Retinoblastoma; cancer cells culture Deng et al., 2019
Proliferating Crocetin: 0, 50, 100, and 200 μM RPE cells culture Wang et al., 2017
Vitreo-retinopathy Crocetin: 0, 100, 200 and 400 μM RPE cells culture Zhang et al., 2019
Crocetin: 0.4 μmol/eye PVR-induced by i.v. ARPE-19 cells Wang et al., 2019
AMD: Age-related macular degeneration; LPS: lipopolysaccharide; NMDA: N-methyl-D-aspartate; OHT: ocular hypertension; POAG: primary 
open angle glaucoma; PVR: proliferative vitreoretinopathy; RP: retinitis pigmentosa; RPE: retinal pigment epithelial cells.
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prevents the significant loss of Brn3a+ RGCs in OHT eyes, at 
7 days after OHT laser induction (Fernández-Albarral et al., 
2019). This neuroprotective effect of the saffron extract could 
be due to its anti-inflammatory effects and its antioxidant 
capacity (Fernández-Albarral et al., 2019). 
The only studies on using saffron in patients with glauco-
ma are focused on analyzing its possible ocular hypotensive 
effect, and have obtained contradictory results. In a random-
ized controlled pilot study on patients with primary ocular 
angle glaucoma, saffron supplementation (1 g twice a week) 
did not appear to affect intraocular pressure in the short 
term (1 month) (Hecht et al., 2019). However, in another 
pilot study, a dosage of 30 mg/day aqueous saffron extract 
orally for three weeks produced a decrease of the intraocular 
pressure in patients with primary ocular angle glaucoma 
(Jabbarpoor Bonyadi et al., 2014). 
Age-related macular degeneration
AMD is a neurodegenerative ocular disorder, in which 
pathogenesis involves chronic inflammation (Buschini et 
al., 2011) and oxidative stress (Beatty et al., 2000). Changes 
in the photoreceptor cells and the retinal pigment epithelial 
cells (RPE) are early events (Johnson et al., 2003) that cause 
loss of visual function. Subtle visual losses, caused by the 
alteration in the function of the different subpopulations 
of photoreceptors and/or by their post-receptoral neurons 
can be recorded by electrophysiological and psychophysical 
techniques (Mayer et al., 1992a, b; Phipps et al., 2003).
Long-term light exposure has been related to the patho-
genesis of AMD. The experimental model of light exposure 
is the main model used in experimental studies of AMD. In 
animal models and in AMD patients, saffron treatment has 
been shown to have beneficial effects on the degenerative 
progression of AMD (Bisti et al., 2014). In an albino rat light 
exposure-induce damage model, saffron-treated healthy reti-
nas showed no saffron metabolites, however, in damaged ret-
inas treated with saffron, crocin was detected in the retinal 
tissue due to the blood retinal barrier breakdown (Bisti et al., 
2014). In a rodent model of light-induced damage, crocetin 
oral administration prevented decreases both the a-wave 
and b-wave amplitudes of the flash electroretinogram; it also 
reduced the number of TUNEL+ cells in the retinal outer 
nuclear layer and inhibited a decrease in the thickness of 
this layer. Crocetin could reduce photoreceptor apoptosis 
by suppressing the increase in caspase 3 and caspase 9 ac-
tivities after retinal damage (Yamauchi et al., 2011). It has 
been shown that saffron treatment could be very effective in 
maintaining retinal morphology by decreasing metallopro-
teinase activation in an AMD albino rat experimental mod-
el. This suggests a new way of setting crocin apart from the 
other known mechanisms, such as free radical scavenging 
(Di Marco et al., 2019). In addition, crocus analogs isolated 
from saffron produce a notable increase in retinal and cho-
roidal blood flow and produced an amplitude recovery of the 
b-wave, thereby facilitating the recovery of retinal function 
after acute retinal ischemia (Xuan et al., 1999). 
The P2X7 receptor (P2X7R) is related to retinal neurode-
generative diseases, such as AMD and retinitis pigmentosa. 
P2X7R is found in cells of different layers of retinal tissue, in-
cluding microglial cells, and is responsible for the modulation 
of the health and signaling of the cells (Vessey et al., 2012). 
This receptor is distinguish by two statuses of permeability 
that lead a intracellular Ca2+ concentration ([Ca2+]i),  increase, 
which could be essential  for cell function (Surprenant et al., 
1996). Studies in vitro have shown that saffron decreases the 
[Ca2+]i response provoked  by purinergic P2X7R stimula-
tion, thereby revealing a new mechanism by which saffron 
can achieve protective activity in neurodegenerative diseases 
(Corso et al., 2016).
Saffron has also been used in clinical studies to test its 
possible neuroprotective effects on AMD patients. In early 
AMD, short-term treatment with saffron enhances retinal 
flicker sensitivity generated in the electroretinogram by 
photoreceptors and bipolar cells, improving visual function. 
Saffron could reverse the damage of these cells caused by ox-
idative stress (Falsini et al., 2010). In addition, in early AMD, 
saffron treatment induces macular function ameliorations 
from baseline that are widespread over long-term follow-up 
(Piccardi et al., 2012), though this improved independently 
of the two major risk genotypes (CFH and ARMS2) re-
lated to AMD (Marangoni et al., 2013). In addition, long-
term daily supplementation with saffron was related with 
a statistically significant shift in macular optical coherence 
tomoqraphy and electroretinogram parameters in AMD pa-
tients, both in the dry and in the wet type, which ameliorat-
ed retinal functions (Lashay et al., 2016). Saffron treatment 
additionally can lead to a mid-term, significant amelioration 
in retinal function in mild/moderate AMD patients, includ-
ing those using the age-related eye disease study (AREDS)
supplements. Saffron supplementation was both efficacious 
and safe in preserving retinal function. However, clinically, 
the degree of response obtained with this study was small 
(Broadhead et al., 2019). Recently, in a comparative study on 
AREDS treatment and saffron treatment in AMD patients, 
visual function remained stable in saffron treated AMD pa-
tients and deteriorated in the AREDS group. The difference 
between both studies was that in AREDS, the components 
are only antioxidants, while saffron has other effects, such 
as its anti-inflammatory properties, in addition to its anti-
oxidant capacity. This study supports the benefit of saffron 
treatment compared to pure antioxidant supplementation (Di 
Marco et al., 2019).
Diabetic retinopathy
Diabetic retinopathy (DR) is one of the main complications 
of diabetes mellitus. DR is related to different etiopathogenic 
mechanisms, such as oxidative stress, apoptosis, and inflam-
mation (Domingueti et al., 2016; Yaribeygi et al., 2019a), 
which leads to RGC degeneration and loss (Barber, 2003). 
Several studies show the hypoglycemic effects of saffron, 
due to its capacity to inhibit the pathophysiologic pathways 
related to insulin resistance, such as oxidative stress and 
inflammation. It has been postulated that saffron is able to 
ameliorate insulin resistance in pre-diabetic patients through 
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different mechanisms: i) inhibition of β-cell failure, ii) in-
creased glucose uptake by insulin‐dependent tissues, iii) im-
provement of glycemic control (Yaribeygi et al., 2019b). 
In a BV-2 and N9 microglial cell culture, following hyper-
glycemic and hyperlipidemic treatment in order to induce 
an experimental diabetes, crocin decreased microglial acti-
vation through its anti-oxidant and anti-inflammatory prop-
erties. These neuroprotective effects could be due to the acti-
vation of the PI3K/Akt signaling pathway. Thus, the authors 
concluded that crocin could be used to control microglial 
activation in DR patients (Yang et al., 2017). These neuro-
protective and anti-oxidant effects have also been observed 
in diabetic macular edema patients previously treated with 
photocoagulation and anti-vascular endothelial growth fac-
tor, in combination with crocin oral supplementation. Cro-
cin decreased the central macular thickness and improved 
the best-corrected visual acuity in these patients (Sepahi et 
al., 2018).
Retinitis pigmentosa
Retinitis pigmentosa (RP) constitutes a neurodegenerative 
dystrophy group characterized by peripheral visual loss 
and hemeralopia that can be accompanied by central vision 
impairment. The oxidative stress leading to photoreceptor 
apoptosis is implicated in the pathogenic mechanism (Remé 
et al., 1998). Most cases of RP are caused by mutations in the 
rhodopsin-encoding gene, with P23H being the main muta-
tion of this gene (Dryja et al., 1990). In a model of autosomal 
dominant RP (P23H rats), safranal treatments ameliorated 
the loss of photoreceptors and protected their electroretino-
graphic response, showing higher amplitudes for both phot-
opic and scotopic responses in animals treated with safranal. 
Furthermore, these treatments preserved the photoreceptors’ 
synaptic contact with other postsynaptic neurons, thus im-
proving retinal function and ameliorating vascular network 
disruption. These authors postulated that safranal treatment 
could be useful in patients with retinitis pigmentosa to help 
delay retinal degeneration (Fernández-Sánchez et al., 2012, 
2015). Saffron protected retinal photoreceptors in a light 
damage model of photoreceptor degeneration in rats (Mac-
carone et al., 2008; Marco et al., 2013). Saffron supplemen-
tation, in combination with photobiomodulation (low-level 
infrared radiation), produced a decrease in photoreceptor 
death, thereby improving their viability and reducing the 
Müller cell glial fibrillary acidic portein up-regulation (Mar-
co et al., 2013). In addition to the model mentioned above, 
saffron extract not only improved the photoreceptors’ mor-
phological features, but also their functional characteristics, 
as revealed by their flash electroretinogram responses (Mac-
carone et al., 2008).
It has also been shown in an experimental mouse model of 
light-induced retinal damage that oral crocetin supplemen-
tation significantly diminished photoreceptor degeneration, 
thereby preventing decreases in both a-wave and b-wave 
flash electroretinogram response amplitudes and improving 
inner retinal function. It also inhibited a decrease in the 
outer nuclear layer thickness and halved the expression of 
TUNEL-positive cells in this layer (Yamauchi et al., 2011). In 
this same work, the effects of crocetin administration in an 
RGC-5 cell culture (a mouse ganglion cell-line transformed 
using the E1A virus) were also analyzed. After the damage 
induced by exposure to tunicamycin and hydrogen peroxide, 
it was demonstrated that crocetin inhibited RGC-5 cell death 
by 50–60%, decreasing the activity of caspase 3 and 9 (Yam-
auchi et al., 2011).
Other Ocular Diseases
Saffron supplementation has also been used in non-neuro-
degenerative ocular diseases, showing the beneficial effects 
of this natural compound (Table 1 and Figure 1).
Myopia
The notable increase in the number of myopia cases in re-
cent years shows the need to find novel treatments that can 
decrease myopia progression. In a murine model of lens-in-
duced myopia, it was shown that crocetin oral treatment can 
improve the refraction shift and decrease axial length, togeth-
er with an increase in choroidal thickness (Mori et al., 2019a). 
A clinical study also showed crocetin’s effect in the control of 
myopia progression in children aged between 6 and 12 years 
old. Two parameters were evaluated in order to test the effi-
cacy of crocetin supplementation. Both spherical equivalent 
refractions and axial length were significantly larger in the 
untreated group (–0.41 ± 0.05 D; 0.21 ± 0.02 mm, respective-
ly) than in the crocetin treated group (–0.33 ± 0.05 D; 0.18 ± 
0.02 mm, respectively) (Mori et al., 2019b).
Retinoblastoma
Retinoblastoma is the most common primary malignant eye 
tumor in children. Among the genes involved in its devel-
opment, MYCN is a transcription factor proto-oncogene, 
whose overexpression or amplification occurs in retinoblas-
toma. Crocin has anti-tumorigenic effects on human reti-
noblastoma cell lines in a MYCN-dependent manner, which 
could contribute to the prevention and treatment of retino-
blastoma (Deng et al., 2019).
Proliferating vitreoretinopathy
Proliferative vitreoretinopathy (PVR) constitutes the most 
important complication after rhegmatogenous retinal de-
tachment. PVR is characterized by the formation of fibrotic 
membranes that can contract and lead to tractional retinal 
(re-)detachment (Ryan, 1985). The main type of cell found 
in fibrotic membranes is RPE. These cells undergo an epi-
thelial-mesenchymal transition  and transform into myofi-
broblast-like cells, and acquire migratory abilities, become 
resistant to apoptosis and generate  extracellular matrix con-
stituents. The epithelial-mesenchymal transition  process of 
RPE is important in PVR development (Tamiya et al., 2010). 
In a study conducted by Wang et al. (2017), the effect of 
crocetin on proliferation, migration, and epithelial-mesen-
chymal transition in ARP-19 cells (a human retinal pigment 
epithelial cell line) was investigated. In this work, it was 
found that crocetin causes the inhibition of the mechanisms 
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mentioned above in RPE cells, mediated by transforming 
growth factor-β2. In another study, it was demonstrated that 
the administration of crocetin could inhibit the migration 
and proliferation of the cell line ARPE-19 by modulating 
the regulators of the Bcl-2 family in a concentration- and 
time-dependent manner. The authors postulated the possible 
role of crocetin in the treatment of PVR (Zhang et al., 2019). 
In addition, other work evaluated the toxicity, pharmaco-
kinetics and possible inhibitor effect of PVR in rabbit eyes 
of intraocular crocetin in an experimental PVR model in-
duced with an intravitreal injection of ARPE-19 cells. After 
crocetin treatment, the authors did not observe toxicity and 
found that crocetin significantly inhibited PVR progression, 
together with the reduction in the expression of α-SMA (a 
mesenchymal marker), Ki67 (a marker of cellular prolifera-
tion), and collagen fibers (Wang et al., 2019).
Conclusion
Studies focused on saffron’s properties show the efficiency 
of saffron supplementation and of its compounds on ocular 
diseases, especially in neurodegenerative diseases. Several 
ethiopatogenic mechanisms are implicated in neurodegen-
erative impairment, including oxidative stress, neuroin-
flammation, and neural cell apoptosis. The main effective 
compound of C. sativus is crocetin, which has antioxidant, 
anti-inflammatory, and anti-apoptotic properties and is able 
to act against the ethiopatogenic mechanisms mentioned 
above. Both experimental and clinical studies support the 
possible therapeutic role of saffron in ocular diseases. 
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